ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / VMD
PARK (60) AGL (36) PGNY (79) CCEL (70) ⌘ Pro Terminal →

Viemed Healthcare Inc. (VMD) — RQD Stock Rating Cockpit

$9.67 -2.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.64

Viemed Healthcare Inc. (VMD) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (58% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate) →
ROARABLE B • BUY Cap $368.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Viemed Healthcare Inc. (NASDAQ: VMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $9.67 (-2.81% 1D, market cap $368.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, VMD ranks #64 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VMD compare to PARK and AGL in the Health Care sector?
▼

Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable B (72/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and AGL (agilon health inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.43B). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VMD?
▼

Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.64 (-0.27%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 4.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+
Cash (16)Whales (9)SEC (18)Macro (14)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$13 Bull$10 Base$8 Bear
📬 FREE VMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VMD)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY VMD SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 6.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($11.9M FCF) & 57.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$9.61+2% Next Q
Q2 (-2Q)
67
Grade B-$9.80-1.2% Next Q
Q3 (-1Q)
69
Grade B-$9.68-0.1% Next Q
Current
72
Grade B$9.67+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, VMD faces multiple-compression risk if 24.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 55.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.26) or 200D SMA ($9.59) invalidates the momentum regime and cuts Target Base ($10.28) toward Bear Floor ($7.93).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
51.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
6.59>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE55% OF RANGE
L: $6$9.67H: $13
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (58% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 32 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on VMD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

13.0% ROIC with 57.5% gross margin and 3.15% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 6.59 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (63)

24/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like VMD
  • ✓Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VMD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.00%▲ ASCENDING CHANNEL
2026-11-03O $9.95H $9.95L $9.67C $9.67VOL 119.5K
RES: $10.26SUP: $8.63SMA50: $9.26SMA200: $9.59
$12.96$11.51$10.05$8.60$7.15RES $10.26SUP $8.63$9.672026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VMD Butterfly Map → + Track VMD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
18.3%/yr Implied 5Y Growth

vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VMD)

Health Care Rank #64 of 1016 ⚔️ PARK vs VMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VMD vs. PARK, AGL, PGNY, CCEL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Viemed Healthcare Inc. (VMD) ranks #64 by composite RQD confidence (72/100, grade B) and #489 by equity capitalization ($368.3M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with VMD at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VMD ACTIVE
Viemed Healthcare Inc.
B 72/100 24.6x 57.5% 13.0% -2.81% $368.3M Benchmark Subject
PARK
Park Dental Partners Inc.
C- 60/100 — — — +5.14% $100.3M /park-vs-vmd →
AGL
agilon health inc.
D- 36/100 — — -35.0% -1.21% $1.43B /agl-vs-vmd →
PGNY
Progyny Inc.
B+ 79/100 37.2x 23.6% 16.7% +2.78% $2.24B /pgny-vs-vmd →
CCEL
Cryo-Cell International Inc.
B- 70/100 — — 18.2% +0.48% $42.0M /ccel-vs-vmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729149

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viemed Healthcare Inc. (VMD) reported GAAP revenue of $270.3M (+20.5% vs. FY2024 revenue of $224.3M , and +47.7% cumulative change since FY2023) , GAAP net income of $15.4M, operating cash flow of $51.9M, and free cash flow of $11.9M (+805.2% YoY). On the balance sheet, VMD closed FY2025 with $199.2M in total assets against $11.3M in total debt (Altman Z-Score: 6.59, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $270.3M $15.4M $51.9M $11.9M $199.2M $11.3M
FY2024 (FY) 2024-12-31 $224.3M $11.4M $39.1M $1.3M $177.1M $3.6M
FY2023 (FY) 2023-12-31 $183.0M $10.2M $45.2M $45.2M — —

3. VMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Viemed Healthcare Inc. (NASDAQ: VMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $9.67 (-2.81% 1D, market cap $368.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, VMD ranks #64 in composite RQD confidence.

How does VMD compare to PARK and AGL in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable B (72/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and AGL (agilon health inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.43B). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VMD?

Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VMD trading relative to its 50-day, 200-day, and 52-week technical levels?

VMD last traded at $9.67 (-2.81% on volume of 119,544 shares), positioning the stock +4.43% above its 50-day simple moving average ($9.26) and +0.83% above its 200-day simple moving average ($9.59). Across its 52-week range of $6.05 to $12.61, VMD sits at the 55.2% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($9.12 to $10.22).

VMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VMD stock right now?

Viemed Healthcare Inc. (VMD) currently earns a Roarable Rating of B (Buy — BUY) with 72/100 RQD Confidence. High-quality cash engine (58% profit margin, 13% return on capital) with steady institutional support.

What is VMD's 12-month price target and RQD AI Jury consensus?

VMD's 12-month base price target is $10.28 (range $7.93 to $13.24), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VMD RQD Cockpit VMD 12M Forecast VMD Earnings & Move VMD Dividends & DRIP VMD Insiders & 13F VMD Whale Options VMD Profit Sankey VMD News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VMD — Viemed Healthcare Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:37:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, VMD scores 75 out of 100 (letter grade B, verdict "Roarable Buy — Good Risk/Reward"). The five pillars are:

  • Fundamental Cash Engine: 16 / 20. Per the RQD rating, ROIC is 13% and FCF yield is 3.15%. For an investor, this indicates the business generates a return on invested capital above typical cost-of-capital thresholds, but the 3.15% FCF yield implies the market is paying a modest multiple for each dollar of free cash flow.
  • Whale 13F Flow: 12 / 20. The rating describes institutional accumulation and options positioning. The underlying 13F holdings data is not provided, so the strength of this signal cannot be verified here.
  • Insider Conviction: 15 / 20. The rating cites SEC Form 4 and Congressional PTR cluster flow. The underlying transaction records are not provided in the source data.
  • Macro Regime Fit: 14 / 20. Per the rating and market data, beta is 1.0, meaning the stock is rated as moving in line with the broad market. The sector-sensitivity detail behind this score is not itemized.
  • Forensic Balance Sheet: 18 / 20. Per the rating, Altman Z is 6.59, Piotroski F is 9/9, and Debt/Equity is 0.08. These readings point to strong solvency and financial-quality signals, the highest-scoring pillar.

Investor implications: the strongest supports are balance-sheet quality and ROIC. The main valuation tradeoff is that trailing P/E of 24.6 and forward P/E of 20.7 sit against a 3.15% FCF yield, so upside depends on earnings growth and continued cash conversion. The weakest pillars (whale flow and insider conviction) rest on data not itemized here, so they should be treated as unverified.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
9.95$379.0M24.620.76.60.40%1.0$6.05 - $12.6113%

Business

Viemed Healthcare Inc. (VMD) is listed on NASDAQ in the Health Care sector, Misc Health and Biotechnology Services industry. The profile describes it as a NASDAQ-listed Health Care issuer with a market capitalization of $0.4B. The source data does not detail its products, customer base, or revenue model. Recent headlines reference home respiratory care, sleep, and maternal health, per the news section, but this is headline-level only.

Recent Catalysts & News Wire Analysis

  • Quarterly earnings: A MarketBeat item states VMD is "Set to Post Quarterly Earnings on Wednesday" and another references a Q3 2026 earnings date and estimates. Estimate figures are not provided. (Watch item.)
  • Growth narrative: A TradingView item (GREEN, CATALYST) headlines growth in home respiratory care, sleep, and maternal health.
  • Options and positioning: A Yahoo Finance item asks whether options traders know something about the stock. The underlying options data is not provided.
  • Momentum and technicals: One item references "+1.80% Momentum" and a chandelier-stop framework, sourced to a site with no further detail.
  • Other wire items: Stock Traders Daily ("The VMD Inflection") and additional MarketBeat/Yahoo items carry no substantive data.
  • Risk watch: Price was -0.4% on the day, and the 52-week range is wide ($6.05 to $12.61).
  • Proprietary signals: None. The Butterfly graph reports no supply-chain links and no proprietary signals.

Open Questions

  • What are the reported EPS figures for FY 2023–FY 2025, given EPS is listed as N/A in the financials?
  • What drove the FY 2025 FCF of $11.9M versus $1.3M in FY 2024 and $45.2M in FY 2023?
  • What are the underlying 13F institutional holdings, options data, and Form 4 / Congressional trade records behind the whale-flow and insider pillar scores?
  • What is the upcoming quarterly earnings date and consensus estimate referenced in the news?
  • What is the company's product mix and customer concentration within home respiratory care, sleep, and maternal health?

VMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Viemed Healthcare Inc. (VMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VMD Bull vs. Bear Conversation Board — What's Your Call at $9.67?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $11.74 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is VMD (B • RQD 75/100) a Buy at $9.95?

Welcome to the VMD (Viemed Healthcare Inc.) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Misc Health and Biotechnology Services. Bulls point to capital efficiency (13.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.86 (-21.0%)
Spot @ $9.95

Pump the brakes on VMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on VMD, but look at what you are paying: 24.6x trailing P/E with 57.5% gross margins. Unless Viemed Healthcare Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $11.34 (+14.0%)
Spot @ $9.95

VMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on VMD, the market is fixating on short-term headline noise in Misc Health and Biotechnology Services and ignoring the balance sheet and cash flow trajectory. At $9.95 (52-wk range $6.05 - $12.61), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%